A. Parharidou

Prolonged administration of erythropoietin increases erythroid response rate in myelodysplastic syndromes: a phase II trial in 281 patients

Nikolaos Laoutaris, E. Terpos, X. Yataganas, 2002, British journal of haematology.

Treatment of anemia in low-risk myelodysplastic syndromes with amifostine. In vitro testing of response

S. Akel, E. Terpos, D. Loukopoulos, 2002, Annals of Hematology.

Treatment of high risk myelodysplastic syndromes with idarubicin and cytosine arabinoside supported by granulocyte-macrophage colony-stimulating factor. (GM-CSF).

T. Economopoulos, S. Raptis, E. Papageorgiou, 1996, Leukemia research.